Allero Therapeutics Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
M&A
- Investors
-
2
Allero Therapeutics General Information
Description
Developer of immunotherapies intended for immune-mediated disorders. The company offers non-invasive, patient-friendly treatments designed to induce long-lasting antigen-specific immune tolerance for conditions such as autoimmune diseases, allergic diseases and anti-drug antibodies.
Contact Information
Website
www.allerotherapeutics.com(Operating Subsidiary)
Corporate Office
- Erasmus MC Incubator
- Marconistraat 16
- 3029 AK Rotterdam
- Netherlands
Corporate Office
- Erasmus MC Incubator
- Marconistraat 16
- 3029 AK Rotterdam
- Netherlands
Allero Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 16-May-2022 | Completed | Generating Revenue | |||
| 3. Grant | 16-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 03-Oct-2019 | Completed | Pre-Clinical Trials | |||
| 1. Grant | 01-Sep-2018 | $57.7K | Completed | Pre-Clinical Trials |
Allero Therapeutics Patents
Allero Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4678183-A1 | Treatment of immune diseases by administration of mrna formulations | Pending | 12-Jul-2024 | ||
| WO-2021198220-A1 | Treatment and prevention of secondary inflammation in patients suffering from a viral infection | Inactive | 30-Mar-2020 | ||
| CA-3080253-A1 | Treatment of immune diseases by administration of antigen-specific formulations | Pending | 25-Oct-2017 | ||
| EP-3700552-A1 | Treatment of immune diseases by administration of antigen-specific formulations | Pending | 25-Oct-2017 | ||
| JP-2023159058-A | Treatment of immune diseases by administration of antigen-specific formulations | Active | 25-Oct-2017 | A61K39/35 |
Allero Therapeutics Signals
Allero Therapeutics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Curie Capital | Venture Capital | Minority | ||
| Swanbridge Capital | Venture Capital | Minority |
Allero Therapeutics FAQs
-
When was Allero Therapeutics founded?
Allero Therapeutics was founded in 2016.
-
Where is Allero Therapeutics headquartered?
Allero Therapeutics is headquartered in Rotterdam, Netherlands.
-
What is the size of Allero Therapeutics?
Allero Therapeutics has 5 total employees.
-
What industry is Allero Therapeutics in?
Allero Therapeutics’s primary industry is Drug Discovery.
-
Is Allero Therapeutics a private or public company?
Allero Therapeutics is a Private company.
-
What is Allero Therapeutics’s current revenue?
The current revenue for Allero Therapeutics is .
-
Who are Allero Therapeutics’s investors?
Curie Capital and Swanbridge Capital have invested in Allero Therapeutics.
-
When was Allero Therapeutics acquired?
Allero Therapeutics was acquired on 16-May-2022.
-
Who acquired Allero Therapeutics?
Allero Therapeutics was acquired by Laboratorios LETI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process